Revenue
$0
Fiscal year ended 2018-12-31Operating income
-$8.59M
Fiscal year ended 2018-12-31Free cash flow
-$6.14M
Fiscal year ended 2018-12-31BIO-PATH HOLDINGS, INC. (BPTH) reported revenue of $0 and net income of -$8.58M for the fiscal year ended 2018-12-31. This page shows 5 annual periods of income statement, balance sheet and cash flow figures normalized from BIO-PATH HOLDINGS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|
| Revenue | $0 | $37.00K | $13.00K | $0 | $0 |
| Cost of revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross profit | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating income | -$8.59M | -$8.97M | -$8.48M | -$5.48M | -$4.54M |
| Net income | -$8.58M | -$7.02M | -$6.75M | -$5.47M | -$4.52M |
| Research & development | $4.60M | $5.48M | $5.47M | $3.02M | $1.63M |
| Weighted-average diluted shares | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Pretax income | -$8.58M | -$7.02M | -$6.75M | -$5.47M | -$4.56M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Diluted EPS | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| General & administrative | $3.38M | $3.52M | $3.01M | $2.46M | $2.72M |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|
| Cash & equivalents | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Total assets | $2.54M | $8.86M | $12.20M | $10.76M | $15.48M |
| Current assets | $2.14M | $7.44M | $10.65M | $9.59M | $14.11M |
| Total liabilities | $1.33M | $791.00K | $3.96M | $937.00K | $561.97K |
| Current liabilities | $1.33M | $791.00K | $1.05M | $937.00K | $561.97K |
| Total equity incl. NCI | $1.22M | $8.07M | $8.24M | $9.82M | $14.92M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts receivable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable | $0 | $0 |
| Accounts payable | $587.00K | $52.00K | $69.00K | $54.00K | $41.03K |
Cash flow
| Metric | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|
| Operating cash flow | -$6.12M | -$7.96M | -$8.15M | Unavailable | Unavailable |
| Capital expenditures | $17.00K | $538.00K | $338.00K | $0 | $123.00K |
| Investing cash flow | -$17.00K | -$538.00K | -$338.00K | Unavailable | Unavailable |
| Financing cash flow | $1.18M | $5.08M | $9.01M | Unavailable | Unavailable |
| Net change in cash | -$4.96M | Unavailable | Unavailable | Unavailable | Unavailable |
| Stock-based compensation | $554.00K | $793.00K | $784.00K | $369.00K | $404.00K |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Derived
| Metric | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|
| Free cash flow | -$6.14M | -$8.50M | -$8.49M | Unavailable | Unavailable |
| Gross margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating margin | Unavailable | -24232.4% | -65192.3% | Unavailable | Unavailable |
| FCF margin | Unavailable | -22959.5% | -65276.9% | Unavailable | Unavailable |
| SBC / revenue | Unavailable | 2143.2% | 6030.8% | Unavailable | Unavailable |
| Current ratio | 1.61x | 9.40x | 10.15x | 10.24x | 25.12x |
| Revenue YoY growth | -100.0% | 184.6% | Unavailable | Unavailable | Unavailable |
| Net margin | Unavailable | -18981.1% | -51923.1% | Unavailable | Unavailable |
| R&D / revenue | Unavailable | 14810.8% | 42107.7% | Unavailable | Unavailable |
| CapEx / revenue | Unavailable | 1454.1% | 2600.0% | Unavailable | Unavailable |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BPTH in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-05-20View SEC filing
10-Q · Filed 2026-01-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing
10-K · Filed 2025-03-27View SEC filing
10-Q · Filed 2024-11-14View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.